Samir Parekh, MD, on Investigating Treatment Options for Relapsed Myeloma

Video

The director of translational research in myeloma at the Tisch Cancer Institute discussed investigating sequential T cell redirection therapies.

“Once a patient relapses several times, they start running out of FDA-approved treatment options. And these new, both cellular and bispecific antibody, agents that are on the cusp of being approved are providing hope for those patients. In fact, the initial results from the studies are so promising that they are now being used or tested at least in earlier lines of treatment with combinations of other drugs that are being used to treat myeloma. And that's where our research comes in.”

Sequential use of different T cell redirection therapies, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (BiAb) led to deep and durable responses in patients with relapsed/refractory multiple myeloma following relapse after BiAb therapy, according to new research out of at Mount Sinai’s Tisch Cancer Institute published in Blood Advances.

CGTLive spoke with Samir Parekh, MD, director of translational research in myeloma and co-leader, Cancer Clinical Investigation program, The Tisch Cancer Institute, and member, Icahn Genomics Institute, Icahn School of Medicine, Mount Sinai, to learn more about the unmet needs for patients whose multiple myeloma relapses several times and the questions that remain to be investigated with sequential T cell redirection therapies.

REFERENCE
Mouhieddine TH, Oekelen OV, Melnekoff DT, et al. Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients. Blood Adv. Published online August 2, 2022. doi: 10.1182/bloodadvances.2022007923
Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Related Content
© 2025 MJH Life Sciences

All rights reserved.